Most Recent Articles by Debra Hughes, MS
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.
A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
More Articles by Debra Hughes, MS
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple MyelomaJun 06,2016
Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed GlioblastomaJun 06,2016
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|